MB-WUXI@EC2609A

LEOCH INT'L

STARGLORY HLDGS

INTELLIMARK W27

BEST FOOD HLDG

GAOYU FINANCE

EXTREME VISION

TIAN TU CAPITAL

HSC RESOURCES

EPI (HOLDINGS)

LAP KEI ENGRG

44048

02269

513700

WXXWY

CICC analyst has maintained a Buy rating on Wuxi Biologics (Cayman) with a price target of HK$48.00, while the shares closed at HK$31.54. The analyst consensus is Strong Buy, with a target of HK$45.23, indicating a 43.41% upside. CMB International Securities also supports a Buy rating with a target of HK$39.00.

Tip Ranks

WUXI BIO POFF-D

WUXI BIO

Penghua CSI HK Connect Health Care Composite ETF

WuXi Biologics

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CICC

516930

516500

588130

159506

159615

512290

588250

513120

159837

159849

520690

159992

159316

510660

520880

LABU

159892

159859

CMB International has raised the target price for WuXi Biologics to 39 yuan and maintained a "Buy" rating. The report pointed out that WuXi Biologics' revenue grew by 16.7% last year, and adjusted net profit increased by 17.9%, both exceeding expectations. It is expected that this year's revenue will grow by 13% to 17%, and may be higher due to foreign exchange fluctuations. Revenue and adjusted net profit are expected to continue to grow over the next three years

AASTOCKS

iShares Biotechnology ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Proshares Ultra Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

SPDR S&P Biotech

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

VanEck Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Invesco Biotechnology & Genome ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ALPS Medical Breakthrough

iShares Global Healthcare

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

CITIC International raised the target price of WuXi Biologics to 39 yuan and maintained a "Buy" rating

01801

Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

marketscreener

INNOVENT BIO

Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

UBS has lowered its earnings per share forecast for WUXI BIO for the next two years by 4% to 5%, with the target price slightly reduced from HKD 51.6 to HKD 49.3, maintaining a "Buy" rating. WUXI BIO's performance in the second half of last year met expectations, with revenue growth of 17.2% to RMB 11.8 billion, and net profit attributable to shareholders increased by 38.3% to RMB 2.6 billion, with a gross margin rising to 46%. Management expects revenue growth of 13% to 17% in 2026

UBS lowers WuXi Biologics' earnings per share forecast for the next two years and slightly reduces the target price to 49.3 yuan

Bank of America Securities released a report stating that WUXI BIO's revenue last year increased by 16.7% year-on-year to 21.8 billion RMB, with a gross profit of 10 billion RMB and a gross margin rising to 46%. The net profit was 4.9 billion RMB, a year-on-year increase of 46.3%. The bank has lowered its revenue forecasts for 2026 to 2028 by 4% to 8%, reduced the gross margin by 0.4 percentage points, and decreased the target price from 47 RMB to 39.5 RMB, maintaining a "Neutral" rating

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

According to "The Big Banks," Bank of America Securities has lowered the target price for WUXI BIO to 39.5 yuan with a rating of "Neutral."

159570

512010

02359

CICC released a report stating that WuXi AppTec's 2025 performance meets expectations, with revenue of 45.456 billion RMB, a year-on-year increase of 15.8%; net profit attributable to the parent company is 19.151 billion RMB, a year-on-year increase of 102.7%. It is expected that total revenue in 2026 will reach 51.3 billion to 53 billion RMB, with a continuous growth of operating business revenue by 18%-22%. The net profit forecasts for 2026 and 2027 are maintained at 17.03 billion RMB and 19.13 billion RMB, respectively, with A/H share ratings of "outperforming the industry," and target prices of 123.5 RMB and 135 HKD, respectively

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

WuXi AppTec

WUXI APPTEC

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

CITIC Securities: WuXi AppTec's performance last year met expectations, maintaining earnings forecast

Nomura maintains a "Buy" rating on WUXI BIO, with a target price of 50.54 yuan. The report points out that WUXI BIO's revenue in the second half of last year increased by 17% year-on-year to 11.8 billion yuan, and profit grew by 38% to 2.57 billion yuan, with gross margin and operating profit margin at 48.7% and 33.7%, respectively. Non-IND and late-stage service revenue grew by 29.4% and 27.7%, while revenue in North America increased by 17%. Management expects revenue growth of 13% to 17% this year, with capital expenditures of approximately 7.1 billion yuan, aiming to achieve positive free cash flow

"Big Banks" Nomura: WUXI BIO maintains "Buy" rating with a target price of 50.54 yuan

Wuxi Biologics posts FY revenue of RMB21,790.0 million

Wuxi Biologics posts FY revenue of RMB21,790.0 million

WuXi AppTec Shares Rise After Strong Annual Results

Direxion S&P Biotech Bear 3X

VG Health

iShares US Pharma

WuXi AppTec Shares Rise After Strong Annual Results

A17U. hopefully wont put a dent to its share price even after money raised. positive news overall i guess.

For SingTel, I will add when there is more pullback.

Dacai

Although Singtel's stock plunged 5.4% due to a network outage, its performance has always been strong and it's still a quality stock. Buy!

Apple

Tiffany lover

Total asset size ranks among the top 2% of account holders
Calculated based on  your Longbridge (Singapore) A/C

Total Assets

Alibaba chip strategically important for China AI, but not a near term threat to NVIDIASK Hynix HBM push confirms strong AI demand bullish for Micron Technology, but Hynix stays aheadSingtel drop short term risk remains better to wait, but attractive on deeper dips for yield investors

Victor y

Total asset size ranks among the top 50% of account holders
Calculated based on  your Longbridge (Singapore) A/C

Commemorative

Hi guys ☕️ Big news: Alibaba dropping a new chip? SK Hynix goes all in on HBM. Apple teases a big one at WWDC. Singtel tanks 5.4%. CapLand Ascendas REIT goes big. Plus 6 earnings. What's catching your eye? 👇

XL2CSOPHYNIX

SingTel

Alps Active REIT ETF

Apple Group

Invesco QQQ Trust

Proshares UltraPro QQQ

SPDR S&P 500

CapLand Ascendas REIT

Sarine Tech

Alibaba

BABA-W

XIAOMI-W

MIXUE GROUP

SENSETIME-W

HESAI-W

GameStop

SingTel 10

Singtel

BABA-WR

Alibaba HK SDR 5to1

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

SENSETIME-WR

Hesai

Crossamerica Partners LP

☕️ Daily Market Talk | March 24, 2026

Seriously, Singtel stop making my life hard. I need the connectivity. Can't believe they are so terrible. I am cancelling my plan with them and will short it!

I believe Alibaba is going to surprise the market with a major new chip product. 💪🏽It is also surprising that no one is talking about yesterday’s gold movement. Gold has never, in history, dropped 10% and then rebounded 10% in a day. The decline itself was the first of its kind in 40 years.

Singtel -5.4% on outage is a buying opportunity if you believe network reliability is fixable. Core business unchanged

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

BITFIRE GROUP

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

MB-WUXI@EC2609A(27320.HK)

MB-WUXI@EC2609A Stock Performance Chart

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CICC

CITIC International raised the target price of WuXi Biologics to 39 yuan and maintained a "Buy" rating

Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

UBS lowers WuXi Biologics' earnings per share forecast for the next two years and slightly reduces the target price to 49.3 yuan

According to "The Big Banks," Bank of America Securities has lowered the target price for WUXI BIO to 39.5 yuan with a rating of "Neutral."